VAXCYTE, INC. Other Income and Expense
VAXCYTE, INC. (PCVX) reported Other Income and Expense of $18.48 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:NonoperatingIncomeExpense · last filed 2026-08-05
- VAXCYTE, INC. nonoperating income (expense) for the quarter ending 2026-06-30 was $18.48M, a 69.03% decline year-over-year.
- VAXCYTE, INC. nonoperating income (expense) for the quarter ending 2026-03-31 was $25.23M, a 37.05% decline year-over-year.
- VAXCYTE, INC. nonoperating income (expense) for the quarter ending 2025-12-31 was $27.78M, a 10.71% increase year-over-year.
- VAXCYTE, INC. nonoperating income (expense) for the quarter ending 2025-09-30 was $29.55M, a 19.70% decline year-over-year.
- VAXCYTE, INC. nonoperating income (expense) for fiscal 2025 was $157.05M, a 48.69% increase from fiscal 2024.
- VAXCYTE, INC. nonoperating income (expense) for fiscal 2024 was $105.62M, a 60.58% increase from fiscal 2023.
- VAXCYTE, INC. nonoperating income (expense) for fiscal 2023 was $65.78M.
| Period end | Nonoperating Income (Expense) 3 month | Nonoperating Income (Expense) 6 month | Nonoperating Income (Expense) 9 month | Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.48M 10-Q · filed 2026-08-05 | $43.70M 10-Q · filed 2026-08-05 | $71.48M derived: sum of 3 quarters · filed 2026-08-05 | $101.03M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $25.23M 10-Q · filed 2026-05-06 | $53.00M derived: sum of 2 quarters · filed 2026-05-06 | $82.55M derived: sum of 3 quarters · filed 2026-05-06 | $142.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $27.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $57.33M derived: sum of 2 quarters · filed 2026-02-24 | $116.97M derived: sum of 3 quarters · filed 2026-08-05 | $157.05M 10-K · filed 2026-02-24 |
| 2025-09-30 | $29.55M 10-Q · filed 2025-11-04 | $89.20M derived: sum of 2 quarters · filed 2026-08-05 | $129.27M 10-Q · filed 2025-11-04 | $154.36M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $59.65M 10-Q · filed 2026-08-05 | $99.72M 10-Q · filed 2026-08-05 | $124.81M derived: sum of 3 quarters · filed 2026-08-05 | $161.61M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $40.08M 10-Q · filed 2026-05-06 | $65.16M derived: sum of 2 quarters · filed 2026-05-06 | $101.96M derived: sum of 3 quarters · filed 2026-05-06 | $126.24M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $25.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $61.89M derived: sum of 2 quarters · filed 2026-02-24 | $86.17M derived: sum of 3 quarters · filed 2026-02-24 | $105.62M 10-K · filed 2026-02-24 |
| 2024-09-30 | $36.80M 10-Q · filed 2025-11-04 | $61.08M derived: sum of 2 quarters · filed 2025-11-04 | $80.53M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $24.28M 10-Q · filed 2025-08-06 | $43.73M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $19.45M 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $65.78M 10-K · filed 2026-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |